OA02.06 PSM Analysis Results from REFRACT: A Multi-Center Cohort Study Investigating the Treatment Patterns in EGFR-Mutant Unresectable LA- NSCLC

Recognizing the paucity of data for patients with unresectable locally advanced non-small cell lung cancer (LA-NSCLC) harboring EGFR mutations, we conducted a pooled, retrospective analysis using collaboration data from 12 major academic cancer institutions in China (REFRACT study) to address this evidence gap. We found that combined RT and EGFR--tyrosine kinase inhibitors (TKIs) with or without chemotherapy (TKI+RT) was independently associated with improved PFS and OS relative to EGFR-TKI treatment alone until tumor progression; TKI+RT was independently associated with improved PFS relative to chemoradiotherapy (CRT), but not OS.